Market Place
Sourcing Support
Hetero Labs Generic Ertugliflozin Receives Tentative Approval in US
17 Apr 2024 //
FDA
Zenara`s Generic Ertugliflozin Receives Approval in the U.S.
04 Apr 2023 //
FDA
FDA Confirms Paragraph IV Patent Litigation for Ertugliflozin
08 Feb 2022 //
FDA
Ertugliflozin Reduces Likelihood of Insulin Initiation in Insulin-Naive Patients
29 Jun 2021 //
FIRSTWORDPHARMA
Merck`s Steglatro shows limited promise with heart failure hospitalization data
31 Aug 2020 //
FIERCEPHARMA
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Endpoint
17 Jun 2020 //
PRESS RELEASE
ADA: Merck, Pfizer`s Steglatro rings up CV safety win but still lags heart
17 Jun 2020 //
FIERCE PHARMA
Steglatro rings up CV safety win but still lags SGLT2 peers
16 Jun 2020 //
FIERCE PHARMA
NICE recommendation for Steglatro in type II diabetes
28 Mar 2019 //
PHARMA TIMES
Diabetes drugs in SGLT2 inhibitor class linked to pancreatitis genital infection
27 Mar 2019 //
PHARMABIZ
SMC OK`s four meds for NHS use, including Roche`s Perjeta
15 Jan 2019 //
PHARMA TIMES
How One Class Of Diabetes Meds May Lead To Flesh-Eating Genital Infections
01 Sep 2018 //
FORBES
FDA slaps gangrene warning on SGLT2 diabetes drugs
31 Aug 2018 //
FIERCE PHARMA
Prescription med: registration of new chemical entities in Australia
09 Jul 2018 //
TGA
Merck`s Steglatro (ertugliflozin) Receives Approval In Europe
06 Apr 2018 //
EMA
Merck`s Steglujan (ertugliflozin / sitagliptin) Receives Approval In Europe
05 Apr 2018 //
EMA
EMA panel recommends Merck, Pfizer`s diabetes drug
26 Jan 2018 //
REUTERS
FDA’s year-end approvals take annual tally to 46
02 Jan 2018 //
PMLIVE
US green light for Pfizer/Merck diabetes therapies
02 Jan 2018 //
PHARMA TIMES
How Large Is Merck`s Phase 3 Drug Pipeline?
29 Dec 2017 //
NASDAQ
FDA Approves SGLT2 Inhibitor STEGLATRO™ Fixed-Dose Combination STEGLUJAN™
22 Dec 2017 //
BUSINESSWIRE
Diabetes Is Officially the Messiest Drug Market
22 Dec 2017 //
BLOOMBERG
U.S. FDA approves new diabetes drug from Merck and Pfizer
21 Dec 2017 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.